Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.35 |
| ▸ | CHIA | Q9BZP6 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 9/20 | 0.35 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | DRD4 | P21917 | 4/20 | 0.35 |
| ▸ | CBX7 | O95931 | 1/20 | 0.34 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.34 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 4/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544933 | 0.85 | MCHR1 (0.41) | CHIT1CHIADRD3DRD2DRD4 | |
| SCHEMBL27995386 | 0.84 | CHRNA7 (0.50) | DRD2L3MBTL3L3MBTL1SMN1; SMN2 | |
| SCHEMBL8728925 | 0.83 | ADRB1 (0.46) | L3MBTL3L3MBTL1SMN1; SMN2CDK4 | |
| SCHEMBL5547171 | 0.81 | KDM4E (0.45) | DRD3DRD2DRD4CBX7CDYL2 | |
| SCHEMBL520505 | 0.81 | MAPT (0.53) | CHIT1CHIADRD3DRD2L3MBTL3 | |
| SCHEMBL8728922 | 0.81 | L3MBTL3 (0.37) | ACKR3CHIT1CHIACBX7CDYL2 | |
| SCHEMBL5547166 | 0.81 | SMN1; SMN2 (0.39) | ACKR3CHIT1CHIACBX7CDYL2 | |
| SCHEMBL5545660 | 0.80 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1 | |
| SCHEMBL7303320 | 0.76 | MAPT (0.51) | SMN1; SMN2 | |
| SCHEMBL12879741 | 0.74 | ADRB1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101351467-A | 3- (substituted amino) -pyrazolo [3, 4-d ] pyrimidines as EphB and VEGFR2 kinase inhibitors | NOVARTIS AG (CH) | 2009-01-21 | — | — | CN | claimed |
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | HOLZER PHILIPP | 2008-11-06 | — | — | US | claimed |
| EP-1963327-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | claimed |
| WO-2007062805-A1 | 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-06-07 | — | — | WO | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ACKR3 144/4885CHIT1 3527/4885CHIA 4752/4885 |
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | EPHB3, EPHB2, EPHB1 | ACKR3 852/4885CHIT1 4521/4885CHIA 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.